New cocktail therapy shows promise for tough esophageal cancer
NCT ID NCT06401447
First seen Apr 26, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to a medium-dose three-drug chemotherapy and radiation can better control advanced esophageal cancer. About 50 participants will receive the treatment over a year, including probiotics and an immune booster. The goal is to see if this approach improves how long patients live without the cancer growing back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
Conditions
Explore the condition pages connected to this study.